Literature DB >> 12196087

The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis.

Marije ten Wolde1, Roderik A Kraaijenhagen, Martin H Prins, Harry R Büller.   

Abstract

BACKGROUND: Little is known about the diagnostic value of a D-dimer test in cancer patients with clinically suspected deep venous thrombosis (DVT).
OBJECTIVE: To evaluate the clinical utility of a whole blood rapid D-dimer test (SimpliRED) in cancer patients compared with noncancer patients.
METHODS: In consecutive patients with suspected lower limb DVT, a D-dimer test and ultrasonogram were performed. Cancer status was recorded at presentation. If the D-dimer test and ultrasonogram results were normal, DVT was considered absent. If the D-dimer result was abnormal, ultrasonography was performed again 1 week later. Anticoagulant therapy was only instituted in those patients with an abnormal ultrasonography result. All patients were followed up for 3 months to record subsequent thromboembolic events. The accuracy of the D-dimer test was assessed, and the efficiency and safety of withholding additional ultrasonography in cancer patients with normal results on both D-dimer and ultrasonography was compared with noncancer patients.
RESULTS: A total of 1739 consecutive patients were studied, 217 (12%) of whom had cancer. The negative predictive value of the D-dimer test was 97% in both cancer and noncancer patients. In 63 (29%) of all 217 cancer patients, the D-dimer and ultrasonography results were normal at referral; therefore, the diagnosis of DVT was refuted and anticoagulant treatment was withheld. In these 63 patients, one thromboembolic event occurred during follow-up (1.6%; 95% confidence interval, 0.04%-8.53%).
CONCLUSIONS: The negative predictive value of a whole blood D-dimer test in cancer patients seems as high as in noncancer patients. In a substantial proportion of cancer patients, the diagnosis can likely be refuted at referral, based on normal D-dimer test and ultrasonogram results. Furthermore, it seems safe to withhold anticoagulant therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196087     DOI: 10.1001/archinte.162.16.1880

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  Update from the clinic: what's new in the diagnosis of cancer-associated thrombosis?

Authors:  Erica A Peterson; Agnes Y Y Lee
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Usefulness of Clinical Prediction Rules, D-dimer, and Arterial Blood Gas Analysis to Predict Pulmonary Embolism in Cancer Patients.

Authors:  Asifa Karamat; Shazia Awan; Muhammad Ghazanfar Hussain; Fahad Al Hameed; Faheem Butt; Ali Saeed Wahla
Journal:  Oman Med J       Date:  2017-03

Review 3.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 4.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

5.  Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes.

Authors:  Oh Young Bang; Jin Myoung Seok; Seon Gyeong Kim; Ji Man Hong; Hahn Young Kim; Jun Lee; Pil-Wook Chung; Kwang-Yeol Park; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee
Journal:  J Clin Neurol       Date:  2011-06-28       Impact factor: 3.077

Review 6.  Effectiveness of d-dimer as a screening test for venous thromboembolism: an update.

Authors:  Swaroopa Pulivarthi; Murali Krishna Gurram
Journal:  N Am J Med Sci       Date:  2014-10

7.  Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis.

Authors:  Noémie Kraaijpoel; Marc Carrier; Grégoire Le Gal; Matthew D F McInnes; Jean-Paul Salameh; Trevor A McGrath; Nick van Es; David Moher; Harry R Büller; Patrick M Bossuyt; Mariska M G Leeflang
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.